Avalo Therapeutics Q2 EPS $(0.59) Beats $(0.80) Estimate, Sales $643.00K Beat $500.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics reported Q2 earnings per share (EPS) of $(0.59), beating the analyst consensus estimate of $(0.80) by 26.25%. This is a 57.25% increase over losses from the same period last year. The company also reported quarterly sales of $643.00K, beating the analyst consensus estimate of $500.00K by 28.60%. However, this is a 37.75% decrease over sales from the same period last year.
August 04, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Avalo Therapeutics reported better than expected Q2 earnings and sales, but showed a decrease in sales compared to the same period last year.
While Avalo Therapeutics beat Q2 earnings and sales estimates, which is generally positive for the stock, the decrease in sales compared to the same period last year could offset this positive impact. Therefore, the short term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100